Immune response to SARS-CoV-2 vaccines in patients with multiple sclerosis in Argentina: prospective and multicenter study

被引：0
|
作者：
Vazquez, G. [1 ,2 ]
Lamas, P. [3 ]
Remolins, C. [3 ]
Appiani, F. [4 ]
Martinez, A. [5 ]
Curbelo, M. C. [5 ]
Pirola, D. [6 ]
Natalia, B. [7 ]
Chuluyan, E. [3 ]
Carra, A. [4 ,5 ]
机构：
[1] Favaloro Fdn Hosp, Buenos Aires, DF, Argentina
[2] INECO, Buenos Aires, DF, Argentina
[3] Univ Buenos Aires, Fac Med, CONICET, CEFYBO, Buenos Aires, DF, Argentina
[4] Favaloro Fdn Hosp, Neurosci, Buenos Aires, DF, Argentina
[5] Britann Hosp, Demyelinating Serv, Buenos Aires, DF, Argentina
[6] Favaloro Fdn Hosp, Cent Lab, Buenos Aires, DF, Argentina
[7] GADOR SA, Med & Sci Dept, Buenos Aires, DF, Argentina
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1113
引用
收藏
页码：879 / 879
页数：1
相关论文
共 50 条
  • [21] Tracking the immune response to SARS-CoV-2 mRNA vaccines in ofatumumab treated RMS patients in a multicenter study (KYRIOS trial)
    Ziemssen, T.
    Schlegel, E.
    Groth, M.
    Ettle, B.
    Bopp, T.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 625 - 625
  • [22] SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Korompoki, Eleni
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    HEMASPHERE, 2021, 5 (03):
  • [23] Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
    Ciampi, Ethel
    Uribe-San-Martin, Reinaldo
    Soler, Bernardita
    Garcia, Lorena
    Guzman, Jorge
    Pelayo, Carolina
    Jurgensen, Lukas
    Guzman, Ignacio
    Vera, Francisco
    Galleguillos, Lorna
    Carcamo, Claudia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 59
  • [24] SARS-CoV-2 vaccines tolerability: A perspective by people with multiple sclerosis
    Di Filippo, Massimiliano
    Gaetani, Lorenzo
    LANCET REGIONAL HEALTH-EUROPE, 2022, 22
  • [25] Humoral immune response to SARS-CoV-2 booster vaccination in patients with multiple sclerosis and healthy controls
    Krajnc, N.
    Riedl, K.
    Hegen, H.
    Traxler, G.
    Leutmezer, F.
    Di Pauli, F.
    Kornek, B.
    Rommer, P.
    Zulehner, G.
    Duerauer, S.
    Bauer, A.
    Kratzwald, S.
    Winklehner, M.
    Deisenhammer, F.
    Guger, M.
    Hoeftberger, R.
    Berger, T.
    Bsteh, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 793 - 793
  • [26] Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis
    Hamzavi, Seyedeh Sadigheh
    Bahrololoom, Rosemina
    Saeb, Sepideh
    Marandi, Nahid Heydari
    Hosseini, Marzieh
    Abadi, Alimohammad Keshtvarz Hesam
    Jamalidoust, Marzieh
    BMC IMMUNOLOGY, 2024, 25 (01)
  • [27] SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines
    De Leon-Rodriguez, Sarai G.
    Hernandez-Rico, Brenda
    Del Olmo-Vazquez, Guadalupe
    Cruz-Davalos, Ivan
    Bonifaz, Laura C.
    BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, 2020, 77 (05): : 252 - 261
  • [28] The Immune Response to SARS-CoV-2: Mechanisms, Aging, Sequelae, and Vaccines
    Espinoza, Carolina
    Alarcon, Marcelo
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2022, 22 (16) : 2166 - 2185
  • [29] Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption
    Groning, Remigius
    Dernstedt, Andy
    Ahlm, Clas
    Normark, Johan
    Sundstrom, Peter
    Forsell, Mattias N. E.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [30] Humoral immune response after SARS-CoV-2 vaccination in cladribine-treated multiple sclerosis patients
    Mimpen, M.
    Kreiter, D.
    Kempkens, T.
    Knippenberg, S.
    Hupperts, R.
    Gerlach, O.
    VACCINE: X, 2024, 16
12345